Locations
Palo Alto, CA, USA · San Francisco, CA, USA
industry
Biotechnology · Data and Analytics · DeepTech · Health · Software
Size
11-50 employees
Stage
Seed
founded in
2018
Menten AI is an early-stage drug discovery company that leverages generative AI and quantum computing to design novel peptide therapeutics. Their platform combines physics-based methods with machine learning to create drug-like molecules efficiently, overcoming traditional limitations in drug design. Menten AI focuses on peptide macrocycles, which are ideal for targeting previously undruggable areas in medicine. The company has demonstrated significant traction with a 10,000x increase in sampling power and a hit success rate exceeding 50%, validated through multiple drug targets, including an anti-viral peptide for Covid-19. Backed by top-tier venture capitalists, Menten AI is positioned to revolutionize drug discovery and development.
Something looks off?